Alumis Inc. $ALMS is Foresite Capital Management VI LLC’s 4th Largest Position

Foresite Capital Management VI LLC lifted its stake in Alumis Inc. (NASDAQ:ALMS) by 1.1% during the second quarter, HoldingsChannel reports. The institutional investor owned 4,247,670 shares of the company’s stock after acquiring an additional 45,000 shares during the period. Alumis accounts for approximately 7.2% of Foresite Capital Management VI LLC’s portfolio, making the stock its 4th biggest position. Foresite Capital Management VI LLC owned about 0.08% of Alumis worth $12,743,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently bought and sold shares of ALMS. Tybourne Capital Management HK Ltd. acquired a new position in Alumis in the second quarter valued at $4,198,000. BML Capital Management LLC lifted its holdings in shares of Alumis by 2,339.0% in the 2nd quarter. BML Capital Management LLC now owns 1,210,415 shares of the company’s stock valued at $3,631,000 after purchasing an additional 1,160,788 shares during the last quarter. Geode Capital Management LLC boosted its position in shares of Alumis by 163.2% in the 2nd quarter. Geode Capital Management LLC now owns 1,167,832 shares of the company’s stock valued at $3,504,000 after purchasing an additional 724,133 shares during the period. Towerview LLC boosted its position in shares of Alumis by 15.1% in the 2nd quarter. Towerview LLC now owns 495,000 shares of the company’s stock valued at $1,485,000 after purchasing an additional 65,000 shares during the period. Finally, Credit Industriel ET Commercial grew its stake in Alumis by 178.8% during the 2nd quarter. Credit Industriel ET Commercial now owns 387,002 shares of the company’s stock worth $1,161,000 after buying an additional 248,202 shares during the last quarter.

Alumis Price Performance

Shares of NASDAQ ALMS opened at $7.30 on Tuesday. The stock has a fifty day moving average price of $4.77 and a 200 day moving average price of $4.28. Alumis Inc. has a 1-year low of $2.76 and a 1-year high of $10.49. The company has a market cap of $762.07 million, a PE ratio of -1.80 and a beta of -1.33.

Alumis (NASDAQ:ALMS) last announced its quarterly earnings data on Thursday, November 13th. The company reported ($1.06) EPS for the quarter, missing analysts’ consensus estimates of ($0.92) by ($0.14). The business had revenue of $2.07 million for the quarter, compared to the consensus estimate of $3.14 million. Analysts anticipate that Alumis Inc. will post -8.51 earnings per share for the current fiscal year.

Insider Activity

In other Alumis news, Director Srinivas Akkaraju purchased 125,743 shares of Alumis stock in a transaction dated Thursday, November 20th. The stock was acquired at an average cost of $7.20 per share, with a total value of $905,349.60. Following the acquisition, the director directly owned 643,260 shares of the company’s stock, valued at $4,631,472. This represents a 24.30% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director James B. Tananbaum acquired 190,500 shares of the company’s stock in a transaction that occurred on Wednesday, November 19th. The shares were acquired at an average cost of $6.56 per share, for a total transaction of $1,249,680.00. Following the acquisition, the director directly owned 2,542,003 shares of the company’s stock, valued at $16,675,539.68. This trade represents a 8.10% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have bought 2,166,882 shares of company stock worth $13,167,830 in the last three months. 40.70% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on ALMS shares. Wall Street Zen downgraded Alumis from a “hold” rating to a “sell” rating in a report on Saturday, November 15th. Morgan Stanley reduced their price target on shares of Alumis from $23.00 to $22.00 and set an “overweight” rating for the company in a research report on Friday, August 15th. HC Wainwright reiterated a “buy” rating and set a $14.00 price target on shares of Alumis in a research note on Thursday, August 14th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Alumis in a research note on Thursday, November 13th. Six research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, Alumis has an average rating of “Moderate Buy” and a consensus target price of $19.20.

About Alumis

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words “allumer”-French for illuminate-and “immunis”-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.